DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for intestinal infectious disease — screening already-approved drugs against its 20-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleIntestinal infectious disease maps to a 20-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for intestinal infectious disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase (ABO) — ABO is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 6-deoxy-alpha-l-galactopyranosyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4Y63 · 1.3 Å · ligand octyl 2-O-(6-deoxy-alpha-L-galactopyranosyl)-beta-D-galactopyranoside (BHE). Experimental structure, not a prediction.
What the evidence adds up to
Immunocompromised patients—those with AIDS, transplant recipients, leukaemia or lymphoma patients, people with inherited immune deficiencies, and patients on immunosuppressive therapy—are at risk for gastrointestinal infections that do not affect healthy hosts. The oesophagus, stomach, small intestine and large intestine can be infected by viruses, bacteria, fungi and protozoa. Symptoms range from fevers of unknown origin to life-threatening haemorrhage and perforation. A 2000 review summarised case reports and studies on pathogens that cause disease uniquely, more frequently, or more severely in this population.
Acute intestinal infections of viral aetiology remain among the most common infectious diseases in childhood. A 2017 article noted wide prevalence, unstable immunity, and a high incidence of mixed infections, resulting in a sustainably high rate of illness. A significant proportion of cases are moderate to severe, placing a heavy burden on national health care. The article provided key data on aetiology, pathogenesis, clinical pattern and treatment, but no specific drug or trial results were reported.
A 1991 review of gastrointestinal infection treatment described three advances: recognition of increasing drug-resistant enteric pathogens and the need to reassess optimal therapy; the growing role of quinolones, especially ciprofloxacin, for enteric fevers; and continued efforts to find more effective therapy for AIDS patients with diarrhoea. No numerical outcomes—survival rates, response rates, or sample sizes—were given for any of these approaches.
What is still missing: controlled trials testing specific repurposed drugs in immunocompromised or paediatric patients with gastrointestinal infections; data on whether ciprofloxacin or other quinolones improve survival or reduce severe outcomes in these groups; and any stratification of patients by pathogen type, immune status, or drug resistance profile.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Gastroenterology · 2000 · 31 citations
Gastrointestinal infections in the immunocompromised host
AbstractImmunocompromised patients, including patients with AIDS, solid organ and bone marrow transplant recipients, patients with leukemia and lymphoma, patients with inherited immune deficiencies, and patients on immunosuppressive therapy for a variety of disorders, are at risk for infections-particularly opportunistic infections, which, by definition, do not infect the healthy host. All systems of the body, including the gastrointestinal tract, are susceptible. The esophagus, stomach, small intestine, and large intestine are sites of infection for viruses, bacteria, fungi, and protozoa. Symptoms can range in severity from fevers of unknown etiology to life-threatening hemorrhage and perforation. This review summarizes recent case reports, clinical studies, and reviews pertaining to pathogens that uniquely cause disease, more frequently cause disease, or cause more severe disease in the immunocompromised host than in the immunocompetent host.
Meditsinskiy sovet = Medical Council · 2017 · 7 citations · open access
ACUTE INTESTINAL INFECTIONS OF VIRAL ETIOLOGY IN CHILDREN: PROSPECTS FOR DIAGNOSIS AND THERAPY
AbstractAcute intestinal infections of viral etiology are among the most common groups of infectious diseases in childhood. The wide prevalence, instable immunity, high incidence of mixed infections result in a sustainably high incidence rate; this, in combination with a significant proportion of moderate to severe forms, is a heavy burden for the national health care. The article provides key data on the etiology, pathogenesis, clinical pattern and treatment of the group of diseases
Current Opinion in Gastroenterology · 1991 · 2 citations
Treatment of gastrointestinal infections
AbstractThe treatment of gastrointestinal infections during 1989 and 1990 advanced on three fronts: first, recognition of the increased prevalence of drug-resistant enteric pathogens and the consequent need to reevaluate optimal therapy; second, the growing role of the quinolones, particularly ciprofloxacin, in the treatment of enteric fevers; and third, the continuing efforts to find more effective therapy for acquired immunodeficiency syndrome (AIDS) patients with diarrhea.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
